当前位置:首页 - 行情中心 - 誉衡药业(002437) - 财务分析 - 现金流量表

誉衡药业

(002437)

  

流通市值:61.24亿  总市值:64.88亿
流通股本:21.04亿   总股本:22.29亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,563,007,514.51,100,814,980.84564,644,445.272,371,185,934.25
  收到的税费返还488,591.96368,869.06247,117.07546,693.48
  收到其他与经营活动有关的现金70,663,837.6243,987,064.5719,877,053.78108,219,340.28
  经营活动现金流入小计1,634,159,944.081,145,170,914.47584,768,616.122,479,951,968.01
  购买商品、接受劳务支付的现金276,098,489.22197,622,409.55102,849,275.27423,728,767.03
  支付给职工以及为职工支付的现金207,560,498.95144,041,042.5877,458,703.98317,706,963.64
  支付的各项税费152,135,557.82110,138,764.5950,895,460.69241,013,926.27
  支付其他与经营活动有关的现金715,190,302.05511,208,040.12280,854,886.91,224,146,797.6
  经营活动现金流出小计1,350,984,848.04963,010,256.84512,058,326.842,206,596,454.54
  经营活动产生的现金流量净额283,175,096.04182,160,657.6372,710,289.28273,355,513.47
二、投资活动产生的现金流量:
  收回投资收到的现金725,167,380625,167,380425,167,3801,268,858,383.65
  取得投资收益收到的现金9,529,378.796,237,460.993,266,043.6741,481,560.14
  处置固定资产、无形资产和其他长期资产收回的现金净额20,484,30519,306,70019,198,00011,420,946.44
  投资活动现金流入小计755,181,063.79650,711,540.99447,631,423.671,321,760,890.23
  购建固定资产、无形资产和其他长期资产支付的现金13,187,799.967,228,556.724,282,920.3123,814,355.98
  投资支付的现金939,038,472.22717,738,472.22175,000,0001,630,000,000
  取得子公司及其他营业单位支付的现金---299,343
  投资活动现金流出小计952,226,272.18724,967,028.94179,282,920.311,654,113,698.98
  投资活动产生的现金流量净额-197,045,208.39-74,255,487.95268,348,503.36-332,352,808.75
三、筹资活动产生的现金流量:
  取得借款收到的现金105,823,162.867,319,650-90,000,000
  筹资活动现金流入平衡项目00-0
  筹资活动现金流入小计105,823,162.867,319,650-90,000,000
  偿还债务支付的现金90,000,00070,000,00070,000,000-
  分配股利、利润或偿付利息支付的现金1,231,626709,145.1340,333.346,830,966.09
  其中:子公司支付给少数股东的股利、利润---5,621,674.43
  支付其他与筹资活动有关的现金4,288,402.873,352,742.453,203,009.72107,219,468.29
  筹资活动现金流出小计95,520,028.8774,061,887.5573,543,343.06114,050,434.38
  筹资活动产生的现金流量净额10,303,133.93-6,742,237.55-73,543,343.06-24,050,434.38
四、汇率变动对现金及现金等价物的影响-3,860,510.37-2,859,825.3-1,436,780.01-1,887,808.59
五、现金及现金等价物净增加额92,572,511.2198,303,106.83266,078,669.57-84,935,538.25
  加:期初现金及现金等价物余额395,837,152.2395,837,152.2395,828,907.76480,772,690.45
  期末现金及现金等价物余额488,409,663.41494,140,259.03661,907,577.33395,837,152.2
补充资料:
  净利润-162,333,510.27-382,357,127.75
  资产减值准备-480,391.82-10,253,095.65
  固定资产和投资性房地产折旧-26,276,552.66-55,603,103.24
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-26,276,552.66-55,603,103.24
  无形资产摊销-17,001,301.64-33,832,277.04
  处置固定资产、无形资产和其他长期资产的损失--12,520,228.38--3,542,703.45
  固定资产报废损失-73,675.14-610,504.12
  公允价值变动损失--4,255,315.28--5,977,821.1
  财务费用-1,127,617.71-4,225,254.36
  投资损失--855,955.72--136,525,191.03
  递延所得税-440,337.95--160,360.82
  其中:递延所得税资产减少-702,399.91--70,640.68
    递延所得税负债增加--262,061.96--89,720.14
  存货的减少-14,040,907.73--19,218,202.55
  经营性应收项目的减少--6,564,249.62--6,626,051.17
  经营性应付项目的增加--17,949,491.75--50,331,385.5
  其他-1,852,751.1-7,498,162.21
  现金的期末余额-494,140,259.03-395,837,152.2
  减:现金的期初余额-395,837,152.2-480,772,690.45
  现金及现金等价物的净增加额-98,303,106.83--84,935,538.25
公告日期2026-10-282026-08-272026-04-282026-04-28
审计意见(境内)标准无保留意见
TOP↑